Ro 6-3129: Difference between revisions
CSV import |
CSV import |
||
| Line 28: | Line 28: | ||
[[Category:Psychoactive drugs]] | [[Category:Psychoactive drugs]] | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
== Ro_6-3129 == | |||
<gallery> | |||
File:Ro_6-3129.svg|Ro 6-3129 | |||
</gallery> | |||
Latest revision as of 21:38, 23 February 2025
Ro 6-3129 is a pharmacological compound that belongs to the class of benzodiazepine drugs. It is a psychoactive drug with sedative, anxiolytic, anticonvulsant, and muscle relaxant properties.
History[edit]
Ro 6-3129 was first synthesized in the 1970s by the pharmaceutical company Roche. It was part of a series of benzodiazepines developed by the company, which also included other well-known drugs such as diazepam (Valium) and clonazepam (Klonopin).
Pharmacology[edit]
Like other benzodiazepines, Ro 6-3129 works by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA is an inhibitory neurotransmitter, which means it reduces the activity of neurons. By enhancing the effect of GABA, benzodiazepines can reduce anxiety, induce sleep, prevent seizures, and relax muscles.
Medical Uses[edit]
Ro 6-3129 has been used in the treatment of various conditions, including anxiety disorders, insomnia, seizure disorders, and muscle spasms. However, its use has been limited due to the risk of dependency and withdrawal symptoms.
Side Effects[edit]
Common side effects of Ro 6-3129 include drowsiness, dizziness, and impaired coordination. Long-term use can lead to dependency and withdrawal symptoms, including insomnia, anxiety, and seizures.
See Also[edit]
Ro_6-3129[edit]
-
Ro 6-3129
